Alex­ion doles out $22M up­front for two pre­clin­i­cal RNAi drugs from Dicer­na

For­mer biotech ace Alex­ion Phar­ma­ceu­ti­cals is still shop­ping to fat­ten its pipeline as it con­tin­ues to shake off a sales prac­tices scan­dal linked to its ex­pen­sive rare dis­ease drug Soliris that cul­mi­nat­ed in an ex­ec­u­tive ex­o­dus and top-to-bot­tom re­or­ga­ni­za­tion. On Wednes­day, the Boston, MA-based com­pa­ny said it would fork out $22 mil­lion up­front to co-de­vel­op two pre­clin­i­cal RNAi ther­a­pies owned by Dicer­na Phar­ma­ceu­ti­cals $DR­NA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER